Modified (m) Folfox7/bevacizumab (B) or modified (m) Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR)

被引：0
|
作者：
Tournigand, C.
Lledo, G.
Delord, J.
Andre, T.
Maindrault-Goebel, F.
Louvet, C.
Scheithauer, W.
de Gramont, A.
机构：
[1] Hop St Antoine, Paris, France
[2] Clin St Jean, Lyon, France
[3] Ctr Claudius Regaud, Toulouse, France
[4] Hop Tenon, Paris, France
[5] Univ Vienna, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4097
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2-Results of the induction phase of the GERCOR DREAM randomized phase III study.
    Tournigand, Christophe
    Chibaudel, Benoist
    Samson, Benoit
    Scheithauer, Werner
    Lledo, Gerard
    Artru, Pascal
    Viret, Frederic
    Ramee, Jean-Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Bonnetain, Franck
    Louvet, Christophe
    Larsen, Annette K.
    Andre, Thierry
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study
    Tournigand, C.
    Samson, B.
    Scheithauer, W.
    Louvet, C.
    Andre, T.
    Lledo, G.
    Latreille, J.
    Viret, F.
    Chibaudel, B.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Phase I trial of erlotinib (E), modified FOLFOX6 (mFOLFOX6), and bevacizumab (B) as first-line therapy for metastatic colorectal cancer (MCRC)
    Singh, D.
    Rath, L.
    Bokar, J. A.
    Brell, J. M.
    Cooney, M. M.
    Dowlati, A.
    Gibbons, J.
    Nock, C. J.
    Savvides, P.
    Krishnamurthi, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.
    Tournigand, Christophe
    Chibaudel, Benoist
    Samson, Benoit
    Scheithauer, Werner
    Lledo, Gerard
    Viret, Frederic
    Andre, Thierry
    Ramee, Jean Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Khalil, Ahmed
    Latreille, Jean
    Louvet, Christophe
    Brusquant, David
    Bonnetain, Franck
    de Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Bevacizumab plus FOLFOX7 as first line treatment for patients (pts) with metastatic colorectal cancer: Preliminary results of a phase II study
    Oukkal, M.
    Salmi, K.
    Abed-Benmelha, N.
    Sefiane, S.
    Djeddi, H.
    Mahfouf, H.
    Bouzid, K.
    ANNALS OF ONCOLOGY, 2007, 18 : VII84 - VII84
  • [6] Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
    Tournigand, Christophe
    Chibaudel, Benoist
    Samson, Benoit
    Scheithauer, Werner
    Vernerey, Dewi
    Mesange, Paul
    Lledo, Gerard
    Viret, Frederic
    Ramee, Jean-Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Latreille, Jean
    Bonnetain, Franck
    Louvet, Christophe
    Larsen, Annette K.
    Andre, Thierry
    de Gramont, Aimery
    LANCET ONCOLOGY, 2015, 16 (15): : 1493 - 1505
  • [7] Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study
    Infante, Jeffrey R.
    Reid, Tony R.
    Cohn, Allen L.
    Edenfield, William J.
    Cescon, Terrence P.
    Hamm, John T.
    Malik, Imtiaz A.
    Rado, Thomas A.
    McGee, Philip J.
    Richards, Donald A.
    Tarazi, Jamal
    Rosbrook, Brad
    Kim, Sinil
    Cartwright, Thomas H.
    CANCER, 2013, 119 (14) : 2555 - 2563
  • [8] Phase II study of bevacizumab (B) plus oxaliplatin (Ox) plus capecitabine (C) followed by bevacizumab (B) plus erlotinib (E) as first-line treatment in metastatic colorectal cancer (mCRC).
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V.
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I.
    Salud, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial
    Tournigand, Christophe
    Samson, Benoit
    Scheithauer, Werner
    Lledo, Gerard
    Viret, Frederic
    Andre, Thierry
    Ramee, Jean Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Khalil, Ahmed
    Latreille, Jean
    Louvet, Christophe
    Brusquant, David
    Bonnetain, Franck
    Chibaudel, Benoist
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study
    Nakayama, Norisuke
    Sato, Atsushi
    Tanaka, Soichi
    Shimada, Ken
    Konishi, Kazuo
    Sasaki, Eisaku
    Hibi, Kenji
    Ichikawa, Hiroko
    Kikuchi, Yoshinori
    Sakuyama, Toshikazu
    Sekikawa, Takashi
    Hayashi, Kazuhiko
    Nishina, Haruhiro
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 954 - 962
12345